<DOC>
	<DOCNO>NCT02683109</DOCNO>
	<brief_summary>This 4-week , multicenter , randomize , double-blind , parallel group active control study . Patients randomize ( 1 1 ratio ) 4-week double-blind treatment period either FDC tiotropium + olodaterol ( 5/5 µg ) plus placebo free combination tiotropium 5 µg olodaterol 5 µg ; administer via Respimat® inhaler . The purpose show non-inferiority FDC free combination tiotropium olodaterol patient COPD .</brief_summary>
	<brief_title>Fixed Dose Combination Versus Free Combination Tiotropium Olodaterol COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Male female patient . Patients 40 year age old . Patients smoke history &gt; 10 pack year . Diagnostic COPD Postbronchodilator FEV1 &gt; = 30 % &lt; 80 % predict normal Postbronchodilator FEV1/FVC &lt; 70 % screening . Symptomatic patient CAT score &gt; = 10 screening . Further inclusion criterion apply . Exclusion criterion : COPD exacerbation symptom low respiratory tract infection within 6 week prior screen . Patients current diagnosis asthma . Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>